USP5 and neoplasm: Moreover, tumors from Usp5 cKO mice treated with Trametinib displayed reduced PD-1 expression and elevated IFN-γ, TNFα, and GzmB in tumor-infiltrating CD8+ T cells (Fig. 6h–k and Supplementary Fig. 10a, b).